Overall survivor benefit exceeds the gold standard 10.7 months vs. 9.9. They just need to either increase the patient enrollment balance out the two European outlier arms. The Hazard ratio will improve if the European outlier patients are pulled from the analysis.
The hazard ratio is fine even without pulling out the outliers. It is a myth of misinformation that a hazard ratio of .75 is somehow bad. There are many drugs approved with hazard ratios of .90 and above.. The survival benefit is the key driver of FDA acceptance here. Remember, this is not a cure for advanced lung cancer. It is just a life extender. That is why all of this garbage from AF and the shorts is just noise.